Avidity gets FDA partial clinical hold lifted on DM1 drug candidate

Iryna Drozd Avidity Biosciences ( NASDAQ: RNA ) said the FDA has lifted a partial clinical hold on its drug candidate delpacibart etedesiran, also known as del-desiran and AOC 1001, for the treatment of myotonic dystrophy type 1, or DM1. The therapy is being evaluated.